2023-11-16 Grand Pharma’s Global Innovative Therapeutic Tumor Vaccine ARC01 China Clinical Trial Application Accepted

2023-10-11 Grand Pharma Acquired 100% Equity of Hubei Bafeng, Further Expanding the Strategic Plan on High-quality Amino Acid Industry

2023-08-09 World’s First Novasight Dual-Mode Intravascular Imaging Catheter Obtained the Import Drug License in China

2023-08-07 Grand Pharmaceutical Group Has Been Selected as a National Talent Introduction Platform

2023-08-07 Grand Pharmaceutical Group’s New MRA Drug Eplerenone Tablets Obtained the Drug License

2021-11-28 GP (HK) Introduces A Global Innovative Mitral Valve Replacement Medical Device – Saturn

2021-11-09 GP (HK)’s Global Innovative Drug STC3141 Successfully Dosed the First Patient of its Phase Ib Clinical Trial for ARDS In China

2021-10-20 GP (HK)’s Global Innovative Drug Ryaltris Compound Nasal Spray Has Been Granted Phase Three Clinical Trial Approval

2021-10-19 GP (HK) Acquires 80% Equity of Huachen BioTech, Accelerating the Globalization Development of Amino Acid Industry

2021-08-11 GP (HK) Announces 2021 Interim Results

2021-08-06 GP (HK) Enters into Strategic Cooperation with CoRISMA on Equity Interests and Products, Introducing a Global Innovative Advanced Heart Failure Therapeutic System

2021-08-02 GP (HK) Enters into Investment and Strategic Cooperation Agreements with FastWave